A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway

被引:226
作者
Erdmann, Kai S.
Mao, Yuxin
McCrea, Heather J.
Zoncu, Roberto
Lee, Sangyoon
Paradise, Summer
Modregger, Jan
Biemesderfer, Daniel
Toomre, Derek
De Camillil, Pietro [1 ]
机构
[1] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA
[3] Yale Univ, Sch Med, Kavli Inst Neurosci, New Haven, CT 06510 USA
[4] Yale Univ, Sch Med, Howard Hughes Med Inst, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06510 USA
[5] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA
关键词
D O I
10.1016/j.devcel.2007.08.004
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
Mutations in the inositol 5-phosphatase OCRL are responsible for Lowe syndrome, whose manifestations include mental retardation and renal Fanconi syndrome. OCRL has been implicated in membrane trafficking, but disease mechanisms remain unclear. We show that OCRL visits late-stage, endocytic clathrin-coated pits and binds the Rab5 effector APPL1 on peripheral early endosomes. The interaction with APPL1, which is mediated by the ASH-RhoGAP-like domains of OCRL and is abolished by disease mutations, provides a link to protein networks implicated in the re-absorptive function of the kidney and in the trafficking and signaling of growth factor receptors in the brain. Crystallographic studies reveal a role of the ASH-RhoGAP-like domains in positioning the phosphatase domain at the membrane interface and a clathrin box protruding from the RhoGAP-like domain. Our results support a role of OCRL in the early endocytic pathway, consistent with the predominant localization of its preferred substrates, PI(4,5)P-2 and PI(3,4,5)P-3, at the cell surface.
引用
收藏
页码:377 / 390
页数:14
相关论文
共 56 条
[41]
Norden AGW, 2002, J AM SOC NEPHROL, V13, P125, DOI 10.1681/ASN.V131125
[42]
OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817
[43]
OTWINOWSKI Z, 1997, FEBS LETT, V528, P27
[44]
CIC-5Cl--channel disruption impairs endocytosis in a mouse model for Dent's disease [J].
Piwon, N ;
Günther, W ;
Schwake, M ;
Bösl, MR ;
Jentsch, TJ .
NATURE, 2000, 408 (6810) :369-373
[45]
PONTING CP, 2006, J CELL BIOL, V98, P1630
[46]
Type II phosphoinositide 5-phosphatases have unique sensitivities towards fatty acid composition and head group phosphorylation [J].
Schmid, AC ;
Wise, HM ;
Mitchell, CA ;
Nussbaum, R ;
Woscholski, R .
FEBS LETTERS, 2004, 576 (1-2) :9-13
[47]
An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway [J].
Shin, HW ;
Hayashi, M ;
Christoforidis, S ;
Lacas-Gervais, S ;
Hoepfner, S ;
Wenk, MR ;
Modregger, J ;
Uttenweiler-Joseph, S ;
Wilm, M ;
Nystuen, A ;
Frankel, WN ;
Solimena, M ;
De Camilli, P ;
Zerial, M .
JOURNAL OF CELL BIOLOGY, 2005, 170 (04) :607-618
[48]
Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells [J].
Stauffer, TP ;
Ahn, S ;
Meyer, T .
CURRENT BIOLOGY, 1998, 8 (06) :343-346
[49]
Peptide-in-groove interactions link target proteins to the β-propeller of clathrin [J].
ter Haar, E ;
Harrison, SC ;
Kirchhausen, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (03) :1096-1100
[50]
Spatial dynamics of receptor-mediated endocytic trafficking in budding yeast revealed by using fluorescent α-factor derivatives [J].
Toshima, JY ;
Toshima, J ;
Kaksonen, M ;
Martin, AC ;
King, DS ;
Drubin, DG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5793-5798